PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: SmallCapReview

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

SmallCapReview to Add Entest Biomedical to its Portfolio - SmallCapReview.com a leading site for small cap information is adding Entest Biomedical (OTCBB: ENTB) to its list of stocks
SmallCapReview to Add Entest Biomedical to its Portfolio

 

NewswireToday - /newswire/ - Winston-Salem, NC, United States, 2009/10/21 - SmallCapReview.com a leading site for small cap information is adding Entest Biomedical (OTCBB: ENTB) to its list of stocks "On the Radar".

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Brokerage/Trading Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Entest Biomedical (ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. The Company is involved with the development of testing procedures for diabetes, stem cell research applications for diabetes, traumatic brain injury and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

ENTB works closely and shares facilities with Bio-Matrix Scientific Group Inc., which is a biotech research and development company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.

The Company is currently in the process of procuring grants from various organizations for conducting research in the area of adipose (fat) derived stem cell treatments for traumatic brain injuries. There are currently no effective therapeutic approaches to reverse these injuries. Entest BioMedical has an exclusive license from UCLA to develop a streamline test for Gestational Diabetes (potentially impacting 4.3 million pregnant women each year).

ENTB Investor Highlights
ENTB is the exclusive licensee, granted by UCLA of a gestational diabetes screening test developed by a UCLA researcher. There are approximately 4.3 million live births in the U.S. per year. Statistics show that out of every 100 pregnant women, 3 to 8 will develop gestational diabetes. Hospitals and clinics represent a large potential market in the U.S. for this non-invasive, reliable, and highly accurate screening test. The Company is currently in the process of developing a large scale sampling for validation by the FDA.

Bio-Matrix Scientific and Entest BioMedical, are working with Therinject to develop immuno-therapeutic cancer treatments initially intended for veterinary applications while gathering data in support of human clinical trials.

The cost of treating Chronic Obstructive Pulmonary Disease (COPD) is projected to exceed $800 billion over the next 20 years. ENTB's stem cell therapy, if proven effective, can provide a strong revenue base for the Company while substantially reducing the cost of treating COPD.

ENTB announced that it has applied for an Exploratory/Development Phase II grant from the National Cancer Institute (NCI).

ENTB anticipates its treatment option could have marked effects on the human oncology market, which the National Cancer Institute (NCI) estimated at more than $72 billion in 2004.

In 2009, NCI’s SEER Cancer Statistics Review estimates that more than 1.4 million men and women in United States will be diagnosed with cancer.

ENTB has plans to develop a commercially viable treatment for canines, which could impact approximately 36 million dogs in United States that suffer from cancer, according to the Morris Animal Foundation and the American Veterinary Medical Association.

Bio-Matrix announced that it has retained a private grant research and development firm to aggressively pursue both private and public sector grant funding of research in the area of Stem Cell Therapy for COPD conducted by Entest BioMedical, Inc.

Bio-Matrix Scientific is in the process of forming a relationship with a medical device manufacturer that produces encapsulation devices to be used in a study developed by ENTB on an immuno-therapeutic cancer vaccine.

Bio-Matrix Scientific announced that the Company and Therinject LLC have begun development of a tumor banking facility. Tumor banking will allow storage and ease of sourcing for tumor cells to be utilized in cancer vaccines.

ENTB filed a patent application for the use of adipose (fat) derived stem cells in the treatment of COPD.

Features available at SmallCapReview.com include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.

No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. SmallCapReview.com has been compensated up to three thousand five hundred dollars by a third party RDI for its services with regards to Entest Biomedical.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Brokerage/Trading Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: SmallCapReview

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Brokerage/Trading articles,
CATCH Visitors via Your Competitors Announcements!


SmallCapReview to Add Entest Biomedical to its Portfolio

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Thomas Englebert - SmallCapReview.com 
336-838-5005 editor[.]smallcapreview.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any SmallCapReview securities in any jurisdiction including any other companies listed or named in this release.

Brokerage/Trading via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From SmallCapReview / Company Profile


Read Brokerage/Trading Most Recent Related Newswires:

SRMEX's Vice Chairman Eikichi Hirano About the Gradual Expansion of Capital Market
Xtrade Wins Best Broker in the Middle East Award
Russian Foreign Trade Reports on Russian Trade with North American Countries Q1 2016
DarkMaindFX Introduces the Beta Version of its Economic Indicator Services
Hermes International Expo to Celebrate 25th Anniversary in Delaware County
GoldSilver Central Approved As Singapore Bullion Market Association Member
OANDA Acquires Tradestation Forex Accounts
[TYPO FOUND BY SYSTEM] Beeline Broking Ltd Launches 'Tailor Made Brokerage Plan'
Signals365.com Announces Key Features - Makes it the Best Binary Options Signals Service
Binary Options Signals from Signals365.com Helps Traders to Get Higher Win-Rate
/RC/ Van Ecker Couder Associates Announce Expansion Program
/RC/ Voth Nixon Group Bolsters Deferred Income Annuity
Grant Becker Associates Chalks Up Another Successful Year of CSR Activities
Evanson Asset Management Dividend Stocks to Safeguard An All-weather Portfolio
AKFinancials Announces its 2015 Forex Course Schedule

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)